Idor­sia’s Jean-Paul Clozel re­tires as CEO, plots next steps; CRISPR Ther­a­peu­tics nabs CMO from Sanofi

Jean-Paul Clozel is ready to pass the torch at his Acte­lion fol­low-up Idor­sia, but he doesn’t want to walk away from the com­pa­ny al­to­geth­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.